The announcement of APVO442, a new bispecific antibody targeting prostate cancer, is a significant development for Aptevo Therapeutics. This innovation, based on their proprietary ADAPTIR-FLEX platform, could enhance the company's product portfolio and market position in the biotech industry. The focus on precision targeting and reduced side effects may attract positive attention from investors, potentially driving the stock price up in the short term.